NASDAQ · PDSB
PDS Biotechnology Corporation
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
Loading market information…
NASDAQ · ABVC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ABVC BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ABVC BioPharma, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ABVC BioPharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 11, 2025 | $0.02+101.15% vs estimate | $1.97K-92.56% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.02+99.0% vs estimate | $389.28K+1,387.15% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$7.77-$0.24 (-3.0%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$1.74-$0.07 (-3.87%)
LAVA Therapeutics N.V.’s quoted price sits in the upper half of its reported 52-week range, 13.0% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$1.94-$0.07 (-3.48%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.55% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$0.73-$0.04 (-5.52%)
Lantern Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.16% below the high.
